Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents

A recent Supreme Court decision has introduced some uncertainty regarding the determination of obviousness of an invention.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. KSR International Co. v. Teleflex Inc. (No. 04-1350).

  2. US Patent No. 6,237,565.

  3. US Patent No. 5,460,061.

  4. US Patent No. 5,819,593.

  5. US Patent No. 5,063,811.

  6. 298 F. Supp. 2d 581; 2003.

  7. Teleflex Ind. v KSR International Co. 04-1152 (119 Fed. Appx. 282; 2005).

  8. Syngenta Seeds, Inc. v. Monsanto Co., 2007 US App. LEXIS 10496 (Fed. Cir. May 3, 2007).

  9. Pfizer v. Apotex (06-1261).

  10. Papesch, 315 F.2d 381.

  11. Sanofi v. Apotex 02 Civ. 2255 (US Dist. 2007).

  12. US Patent No. 4,847, 265.

  13. Takeda Chem. Indus. et al. v. Alphapharm et al., No. 06-1329 (Fed. Cir. 2007).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Teitelbaum, R., Cohen, M. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents. Nat Biotechnol 25, 1105–1106 (2007). https://doi.org/10.1038/nbt1007-1105

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1007-1105

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing